mRNA
A large retrospective study from the University of Florida and The University of Texas MD Anderson Cancer Center, published in Nature, reports that patients with advanced non-small cell lung cancer or metastatic melanoma lived significantly longer if they received a Pfizer-BioNTech or Moderna COVID-19 mRNA shot within 100 days of starting immune checkpoint inhibitors. The authors stress the findings are observational and will require confirmation in randomized trials.
Von KI berichtet
An analysis of nearly 1,000 cancer patients shows that mRNA covid-19 vaccines, given soon after starting immune checkpoint inhibitors, nearly doubled survival times for advanced lung and skin cancers. The findings, presented at a medical congress in Berlin, suggest an unexpected immune boost from the vaccines. A clinical trial to confirm these results is set to begin before year's end.